A phase I trial of figitumumab in children with relapsed/refractory solid tumour
ISRCTN | ISRCTN12655440 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN12655440 |
Secondary identifying numbers | RG_09-071 |
- Submission date
- 19/01/2010
- Registration date
- 15/06/2010
- Last edited
- 04/10/2017
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Prof Kathy Pritchard-Jones
Scientific
Scientific
The Institute of Cancer Research & Royal Marsden Hospital
Downs Road
Sutton
Surrey
SM2 5PT
United Kingdom
Phone | +44 (0)20 8661 3452 |
---|---|
kathy.pritchard-jones@icr.ac.uk |
Study information
Study design | Phase I open-label multicentre study |
---|---|
Primary study design | Interventional |
Secondary study design | Non randomised study |
Study setting(s) | Hospital |
Study type | Treatment |
Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
Scientific title | A phase I open label multicentre trial of figitumumab, an insulin-like growth factor 1 receptor (IGFR-1R) antibody, in children aged 1 - 12 years old with relapsed/refractory solid tumour |
Study acronym | FOREST |
Study objectives | The aim of this study is to identify the maximum tolerated dose of figitumumab. |
Ethics approval(s) | 1. UK: Trent Research Ethics Committee pending as of 15/06/2010 2. France: pending as of 15/06/2010 |
Health condition(s) or problem(s) studied | Relapsed/refractory solid tumours |
Intervention | Figitumumab given on day 1 of a three weekly cycle as a 2.5 hour intravenous (IV) infusion. Starting dose 6 mg/kg with escalation cohorts that include 10 mg/kg, 20 mg/kg and 30 mg/kg. In cycle one only, patients recieve a second identical loading dose given on day 2. Patients can receive up to 12 cycles of treatment providing there is clinical benefit. Follow up is up to 90 days after the last dose received or until the patient receives further therapy for their disease. |
Intervention type | Drug |
Pharmaceutical study type(s) | |
Phase | Phase I |
Drug / device / biological / vaccine name(s) | Figitumumab |
Primary outcome measure | Safety, measured by assessment of adverse events and laboratory abnormalities using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 assessing grade timing, seriousness and relatedness. Outcome will be measured after cycle 1. |
Secondary outcome measures | 1. Pharmacokinetic blood sampling looking at plasma figitumumab concentrations, anti-drug antibodies, serum IGF-1/2, insulin-like growth factor binding protein 3 (IGFCP-3), insulin and growth hormone levels, measured Cycle 1 day 1, 2 and 8 and then prior to cycle 4. Antidrug antibodies measured cycle 1 day 1 and end of treatment. 2. Response to treatment measured by Response Evaluation Criteria In Solid Tumours (RECIST) criteria or by nuclear imaging or histology, measured every 2 cycles |
Overall study start date | 01/08/2010 |
Completion date | 01/08/2012 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Child |
Lower age limit | 1 Year |
Upper age limit | 12 Years |
Sex | Both |
Target number of participants | 24 - 48 depending on the dose escalation required |
Key inclusion criteria | 1. Aged greater than 1 years and less than 12 years, either sex 2. Histological confirmation of solid extra cranial malignancy at original diagnosis 3. Phase 2 cohort only: measureable or clinically evaluable disease 4. Current disase status must be one for which no available curative therapy 5. Performance status Lansky greater than 50% or Eastern Cooperative Oncology Group (ECOG) less than 2 6. Adequate recovery from major surgery prior to treatment 7. No mitral valve regurgitation greater than trivial as determined by Doppler echocardiogram. Shortening of fraction less than or equal to 29%. Electrocardiogram (ECG) should be normal. 8. Must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy. Two weeks from previous chemotherapy, four weeks from previous radiotherapy and six weeks from previous nitrosureas or myeloablative chemotherapy. 9. Adequate bone marrow function 10. Adequate renal function 11. Adequate liver function 12. Males or females of reproductive potential may not participate unless they agree to use an effective contraceptive method 13. All patients and/or their parents or legal guardians must sign a written informed consent 14. Patients and/or their parents and/or legal guardians must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures |
Key exclusion criteria | 1. Concurrent treatment with any anti-tumour agents 2. Prior anti-IGF-1R therapy 3. Patients with symptomatic brain metastases 4. Significant active cardiac disease 5. Active infection 6. Poorly controlled Insulin-dependent diabetes mellitus 7. History of allergic reaction to immunoglobulin G (IgG) 8. Other severe acute or chronic medical or psychiatric condition |
Date of first enrolment | 01/08/2010 |
Date of final enrolment | 01/08/2012 |
Locations
Countries of recruitment
- England
- France
- United Kingdom
Study participating centre
The Institute of Cancer Research & Royal Marsden Hospital
Surrey
SM2 5PT
United Kingdom
SM2 5PT
United Kingdom
Sponsor information
University of Birmingham (UK)
University/education
University/education
Research & Commercial Services
Aitchison Building
Edgbaston
Birmingham
B15 2TT
England
United Kingdom
Website | http://www.rcs.bham.ac.uk/ |
---|---|
https://ror.org/03angcq70 |
Funders
Funder type
Charity
Cancer Research UK
Private sector organisation / Other non-profit organizations
Private sector organisation / Other non-profit organizations
- Alternative name(s)
- CR_UK, Cancer Research UK - London, CRUK
- Location
- United Kingdom
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |
Editorial Notes
04/10/2017: No publications found in PubMed, verifying study status with principal investigator.